메뉴 건너뛰기




Volumn 19, Issue 6, 2008, Pages 1209-1210

COX-2 targeting in cancer: A new beginning?

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; ROFECOXIB; ZILEUTON;

EID: 44849137509     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn286     Document Type: Letter
Times cited : (3)

References (5)
  • 1
    • 0036236186 scopus 로고    scopus 로고
    • Celecoxin: A specific COX-2 inhibitor with anticancer properties
    • Koki AT, Masferre JL. Celecoxin: A specific COX-2 inhibitor with anticancer properties. Cancer Control 2002; 9: 28-35.
    • (2002) Cancer Control , vol.9 , pp. 28-35
    • Koki, A.T.1    Masferre, J.L.2
  • 2
    • 22444441665 scopus 로고    scopus 로고
    • Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis
    • Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. Br Med J 2005; 330: 1366-1369.
    • (2005) Br Med J , vol.330 , pp. 1366-1369
    • Hippisley-Cox, J.1    Coupland, C.2
  • 3
    • 39749149266 scopus 로고    scopus 로고
    • Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-cancer and leukemia group B trial 30203
    • Edelman MJ, Watson D, Wang X et al. Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-cancer and leukemia group B trial 30203. J Clin Oncol 2008; 26: 48-855.
    • (2008) J Clin Oncol , vol.26 , pp. 48-855
    • Edelman, M.J.1    Watson, D.2    Wang, X.3
  • 4
    • 44849110459 scopus 로고    scopus 로고
    • Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: Results of a phase II study with biomarker evaluation
    • doi:10.1007/s00280-007-0650-1
    • Fabi A, Metro G, Papaldo P et al. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 2008; doi:10.1007/s00280-007-0650-1.
    • (2008) Cancer Chemother Pharmacol
    • Fabi, A.1    Metro, G.2    Papaldo, P.3
  • 5
    • 3042524200 scopus 로고    scopus 로고
    • Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma
    • Milella M, Gelibter A, Di Cosimo S et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004; 101: 133-138.
    • (2004) Cancer , vol.101 , pp. 133-138
    • Milella, M.1    Gelibter, A.2    Di Cosimo, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.